Displaying drugs 551 - 575 of 11788 in total
Methyldopa
Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading...
Approved
Matched Description: … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. ... [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …
Human interferon beta
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … significantly debilitating with a profound impact on the quality of life. ... Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis ... It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity. …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... [L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare ... "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a …
Efmoroctocog alfa
Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It...
Approved
Investigational
Matched Description: … Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency ... Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood ... Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... the first therapeutic option for patients with MoCD type A. ... Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a …
Lopinavir
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability...
Approved
Matched Description: … [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold ... Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration …
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Categories: … Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …
Remestemcel-L
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … risk for poor outcomes and creating a significant clinical challenge [A31818]. ... Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal ... aGvHD is a T-cell mediated disease that occurs after allogeneic hematopoietic stem cell transplant and …
Levomilnacipran
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. ... Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Thonzonium
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. …
Viltolarsen
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) ... links between nucleotides are replaced with a phosphorodiamidate linkage. ... Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of …
Clemastine
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Ertugliflozin
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Description: … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes …
Ethotoin
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … Ethotoin is a hydantoin derivative and anticonvulsant. …
Adalimumab
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available ... It is produced by recombinant DNA technology using a mammalian cell expression system. ... Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid …
Alclofenac
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Description: … Alclofenac is a non-steroidal anti-inflammatory drug. …
Apronalide
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Atracurium
Approved
Experimental
Investigational
Crotalus adamanteus antivenin
Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 .
The eastern diamondback...
Approved
Experimental
Paroxetine
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. ... It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic ... [L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition …
Chloroprocaine
Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. The pharmacological profile of...
Approved
Investigational
Matched Description: … [L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration ... Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a …
Pentoxifylline
Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties.[A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for its possible...
Approved
Investigational
Matched Description: … Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties ... [A226410, A226415, A226455] More recently, PTX has been suggested as a possible treatment for COVID-19 ... [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Cholestyramine
Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
Approved
Investigational
Matched Description: … Cholestyramine or colestyramine is a bile acid sequestrant. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Description: … (ESA) with a longer half-life than erythropoietin. ... Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Displaying drugs 551 - 575 of 11788 in total